A "Method of Use" to Prevent Generic and Biosimilar Market Entry

N Engl J Med. 2023 Feb 9;388(6):483-485. doi: 10.1056/NEJMp2216020. Epub 2023 Jan 25.

Authors

S Sean Tu¹, Ameet Sarpatwari¹

Affiliation

¹ From the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (S.S.T., A.S.); and West Virginia University College of Law, Morgantown (S.S.T.).

PMID: 36734878
DOI: 10.1056/NEJMp2216020

No abstract available

MeSH terms

Biosimilar Pharmaceuticals* / economics
Biosimilar Pharmaceuticals* / therapeutic use
Drug Costs
Drug Industry* / economics
Drug Industry* / legislation & jurisprudence
Drugs, Generic* / economics
Drugs, Generic* / therapeutic use
Economic Competition* / economics
Economic Competition* / legislation & jurisprudence
Humans
Patents as Topic* / legislation & jurisprudence

Substances

Biosimilar Pharmaceuticals
Drugs, Generic